腸道免疫細胞占人體的總免疫系統高達70〜80%，因此腸道在面對不斷的免疫刺激、耐受性和免疫反應之間的自體平衡，成為腸道免疫系統控制感染源的必要的條件，由微生物病原體所引發的腸道感染往往會誘導許多發炎性病症，包括食物過敏、發炎性腸道疾病（Inflammatory bowel disease；IBD）和大腸癌。
目前已有許多研究指出，乳酸菌（Lactic acid bacteria）能透過改善腸道微生物菌群和調節免疫系統來達到促進腸道健康的效果。因此，本研究以七株Lactobacillus屬及一株Lactococcus屬的乳酸菌為材料。首先以脂多醣（lipopolysaccharide；LPS）誘發RAW 264.7小鼠巨噬細胞株發炎，同時加入熱處理乳酸菌。結果顯示YM0039（Lactobacillus brevis）及YM0512（Lactobacillus plantarum）對NO生成，與已商業化的Shirota（Lactobacillus casei Shirota）和LGG（Lactobacillus rhamnosus GG）的抑制效果相當（49%～55%）。
接著，利用LPS誘發Caco-2人類上皮大腸癌細胞株發炎。在上述八株熱處理乳酸菌與LPS共同處理時，YM0039雖然對促發炎白細胞介素-8（interleukin-8；IL-8）mRNA表現和蛋白質分泌的抑制效果（43%及34%）略低於Shirota（69%及50%）和LGG（74%及43%），然在統計分析上三者均是無顯著差異（p<0.01）。而在乳酸菌處理10小時後，再以LPS誘發Caco-2細胞發炎上，YM0039具有最佳的55% IL-8 mRNA抑制效果，不過仍不及LGG的79%抑制效果。
實驗結果顯示L. brevis YM0039這株乳酸菌具有顯著抗發炎功效，未來希望能將這株乳酸菌當作一種輔助性的健康食品，應用在IBD的症狀減緩和腸道保健。

中文摘要 1
英文摘要（Abstract） 3
壹、 前言 5
一、 腸道上皮細胞的免疫表現 5
二、 發炎性腸疾病 5
三、 引發腸道發炎的致病菌群 7
四、 腸道致病菌所誘導的發炎反應 8
五、 乳酸菌簡介 11
六、 乳酸菌對於IBD患者的療效 13
貳、 研究動機與策略 15
參、 材料與方法 16
一、 實驗材料 16
(一)、化學藥品、材料與酵素 16
(二)、儀器 17
(三)、細胞株與菌株 18
(四)、培養基及化學試劑配法 18
二、 實驗方法 20
(一)、乳酸菌製備 20
(二)、細胞培養 20
(三)、細胞計數 21
(四)、乳酸菌對LPS刺激RAW 264.7細胞株之NO生成量分析 21
(五)、細胞存活率測試 22
(六)、乳酸菌對LPS刺激Caco-2細胞之處理 23
(七)、RT-PCR 23
(八)、ELISA分析 25
(九)、統計分析 26
肆、 結果 27
一、 乳酸菌同步添加對LPS刺激RAW 264.7細胞株之細胞存活及NO生成影響27
二、 乳酸菌同步添加對LPS刺激CACO-2細胞株之IL-8 MRNA表現影響 28
三、 乳酸菌同步添加對LPS刺激CACO-2細胞株之IL-8分泌蛋白表現影響 28
四、 乳酸菌前處理對LPS刺激CACO-2細胞株之IL-8 MRNA表現影響 29
伍、 討論 30
陸、 參考文獻 34
柒、 圖表 39

1. (2006). Electronic Medicines Compendium, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

2. Abe, F., et al. (1995). "Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets." J Dairy Sci 78(12): 2838-2846.

3. Ando, K., et al. (2010). "Human lactoferrin activates NF-kappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling." Febs j 277(9): 2051-2066.

4. Arseneau, K. O., et al. (2007). "Innate and adaptive immune responses related to IBD pathogenesis." Curr Gastroenterol Rep 9(6): 508-512.

5. Artursson, P. and J. Karlsson (1991). "Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells." Biochem Biophys Res Commun 175(3): 880-885.

6. Baumgart, D. C. and W. J. Sandborn (2012). "Crohn's disease." Lancet 380(9853): 1590-1605.

7. Calabrese, V., et al. (2010). "Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders." Antioxid Redox Signal 13(11): 1763-1811.

8. Desreumaux, P. (2000). "Specific targeting of IL-6 signalling pathway: a new way to treat IBD?" Gut 47(4): 465-466.

9. Devaraj, S., et al. (2008). "Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State." J Clin Endocrinol Metab 93(2): 578-583.

10. Dong, H., et al. (2013). "Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers." Eur J Nutr 52(8): 1853-1863.

11. Ewaschuk, J. B. and L. A. Dieleman (2006). "Probiotics and prebiotics in chronic inflammatory bowel diseases." World J Gastroenterol 12(37): 5941-5950.

12. Faubion, W. A., Jr., et al. (2001). "The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study." Gastroenterology 121(2): 255-260.

13. Forstermann, U. and W. C. Sessa (2012). "Nitric oxide synthases: regulation and function." Eur Heart J 33(7): 829-837, 837a-837d.

14. Fortunato, J. E., et al. (2010). "Outcome after percutaneous endoscopic gastrostomy in children and young adults." J Pediatr Gastroenterol Nutr 50(4): 390-393.

15. Gibson, G. R., et al. (2004). "Dietary modulation of the human colonic microbiota: updating the concept of prebiotics." Nutr Res Rev 17(2): 259-275.

16. Hooper, L. V. and A. J. Macpherson (2010). "Immune adaptations that maintain homeostasis with the intestinal microbiota." Nat Rev Immunol 10(3): 159-169.

17. Hoshino, K., et al. (2002). "Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation." Int Immunol 14(10): 1225-1231.

18. Hwang, H. S., et al. (2014). "Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems." J Korean Med Sci 29(1): 53-60.

19. Jang, S., et al. (2008). "Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1." Proc Natl Acad Sci U S A 105(21): 7534-7539.

20. Li, N., et al. (2012). "Microbial cell components induced tolerance to flagellin-stimulated inflammation through Toll-like receptor pathways in intestinal epithelial cells." Cytokine 60(3): 806-811.

21. Li, N., et al. (2009). "Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats." Pediatr Res 66(2): 203-207.

22. Lozano, R., et al. (2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010." Lancet 380(9859): 2095-2128.

23. Mendes-Ribeiro, A., et al. (2009). "The Role of Exercise on L-Arginine Nitric Oxide Pathway in Chronic Heart Failure." Open Biochem J 3: 55-65.

24. Nomura, M., et al. (2006). "Phenotypic and molecular characterization of Lactococcus lactis from milk and plants." J Appl Microbiol 101(2): 396-405.

25. O'Keefe, S. J. (1996). "Nutrition and gastrointestinal disease." Scand J Gastroenterol Suppl 220: 52-59.

26. Ohland, C. L. and W. K. Macnaughton (2010). "Probiotic bacteria and intestinal epithelial barrier function." Am J Physiol Gastrointest Liver Physiol 298(6): G807-819.

27. Ohmen, J. D., et al. (1996). "Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis." Hum Mol Genet 5(10): 1679-1683.

28. Palsson-McDermott, E. M. and L. A. O'Neill (2004). "Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4." Immunology 113(2): 153-162.

29. Panter, S. J., et al. (2004). "Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome." Aliment Pharmacol Ther 19(9): 981-988.

30. Parkes, G. C., et al. (2010). "Treating irritable bowel syndrome with probiotics: the evidence." Proc Nutr Soc 69(2): 187-194.

31. Peek, R. M., Jr., et al. (2010). "Role of innate immunity in Helicobacter pylori-induced gastric malignancy." Physiol Rev 90(3): 831-858.

32. Robert, M. E., et al. (2004). "Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years." Am J Surg Pathol 28(2): 183-189.

33. Salminen, A., et al. (2011). "AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan." J Mol Med (Berl) 89(7): 667-676.

34. Salminen, S., et al. (1998). "Demonstration of safety of probiotics -- a review." Int J Food Microbiol 44(1-2): 93-106.

35. Scheinfeld, N. S., et al. (2001). "Crohn's disease and lichen nitidus: a case report and comparison of common histopathologic features." Inflamm Bowel Dis 7(4): 314-318.

36. Sears, C. L. (2005). "A dynamic partnership: celebrating our gut flora." Anaerobe 11(5): 247-251.

37. Shokryazdan, P., et al. (2014). "Probiotic Potential of Lactobacillus Strains with Antimicrobial Activity against Some Human Pathogenic Strains." Biomed Res Int 2014: 927268.

38. Stein, J., et al. (2010). "Diagnosis and management of iron deficiency anemia in patients with IBD." Nat Rev Gastroenterol Hepatol 7(11): 599-610.

39. Szliszka, E., et al. (2013). "Inhibition of Inflammatory Response by Artepillin C in Activated RAW264.7 Macrophages." Evid Based Complement Alternat Med 2013: 735176.

40. Valerio, A., et al. (2006). "TNF-? downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents." J Clin Invest 116(10): 2791-2798.

41. Villena, J. and H. Kitazawa (2014). "Modulation of Intestinal TLR4-Inflammatory Signaling Pathways by Probiotic Microorganisms: Lessons Learned from Lactobacillus jensenii TL2937." Front Immunol 4: 512.

42. Vlahopoulos, S., et al. (1999). "Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation." Blood 94(6): 1878-1889.

43. Vo, V. A., et al. (2014). "N-(p-Coumaryol)-Tryptamine Suppresses the Activation of JNK/c-Jun Signaling Pathway in LPS-Challenged RAW264.7 Cells." Biomol Ther (Seoul) 22(3): 200-206.

44. von Schillde, M. A., et al. (2012). "Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines." Cell Host Microbe 11(4): 387-396.

45. Wolff, B., et al. (1998). "Endothelial cell "memory" of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies." J Exp Med 188(9): 1757-1762.

46. Zweibaum, A., et al. (1983). "Sucrase-isomaltase: a marker of foetal and malignant epithelial cells of the human colon." Int J Cancer 32(4): 407-412.

柒、